Navigation Links
Pharmatech 2.0: Introducing Pharmatech Oncology

DENVER, Jan. 5 /PRNewswire/ -- Pharmatech, Inc. announces the launch of a new campaign, Pharmatech 2.0, to highlight the company's focus in oncology, along with other key company developments that will take place in early January 2009. The next generation of Pharmatech will feature a name change from Pharmatech, Inc. to Pharmatech Oncology, Inc., as well as a new web site and emerging roles and responsibilities of the executive leadership team.

With the start of 2009, all business will be managed under the name Pharmatech Oncology, Inc. The Pharmatech Board of Directors implemented the name change from the parent company of Pharmatech, Inc. to the subsidiary name of Pharmatech Oncology. Anders Malm, current President, states, "There was a need in the marketplace for better recognition of what type of business Pharmatech was involved in. Changing from Pharmatech to Pharmatech Oncology relays a core understanding that Pharmatech works within the cancer arena."

The leadership team at Pharmatech Oncology will also be undergoing a transformation in roles and titles. Current Chief Executive Officer, Matthew B. Wiener, PharmD, will now take over the daily business operations under the title Chairman and Chief Operating Officer. Anders Malm, current President, will now replace Dr. Wiener as CEO. Pharmatech Oncology also welcomes Rob Bohacs as the new Corporate Development Manager.

Pharmatech Oncology will also introduce a new web site, The launch of the new web site will showcase a more functional format, along with easy navigation capabilities. The current web site will point to the new address at

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech Oncology, please visit

SOURCE Pharmatech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
2. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
3. WuXi PharmaTech Announces Third Quarter 2008 Results
4. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
5. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
6. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
7. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
8. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
9. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
10. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
11. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, the ... pharmaceutical innovations, today announced it has signed ... Fund (KDDF) to foster collaboration between KDDF and HUYA ... commercialization of healthcare products for the global market. ... important source of new innovative preclinical and clinical stage ...
(Date:11/30/2015)... Florida and MAGDEBURG, Germany , ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... 3rd European Congress of NeuroRehabilitation (ECNR) in ... --> NovaVision, a wholly owned subsidiary of Vycor ... European version of its Internet-delivered NovaVision Therapy Suite at the ...
(Date:11/30/2015)... Israel , Nov. 30, 2015 BrainStorm ... developer of adult stem cell technologies for neurodegenerative diseases, today ... been awarded an additional grant of approximately $735,000 from ... This grant, the second this year, brings the total awarded ... million (approximately NIS7 million).  ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
Breaking Biology Technology:
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
(Date:11/12/2015)... --  Growing need for low-cost, easy to use, ... the way for use of biochemical sensors for ... clinical, agricultural, environmental, food and defense applications. Presently, ... applications, however, their adoption is increasing in agricultural, ... on improving product quality and growing need to ...
Breaking Biology News(10 mins):